Growth hormone inhibits hepatic de novo lipogenesis in adult mice

Diabetes

Volumn 64, Issue 9, 2015, Pages 3093-3103

  Cordoba Chacon, Jose ^a,b   Majumdar, Neena ^a,b   List, Edward O ^c,d   Diaz Ruiz, Alberto ^e   Frank, Stuart J ^f,g   Manzano, Anna ^h   Bartrons, Ramon ^h   Puchowicz, Michelle ⁱ   Kopchick, John J ^c,d   Kineman, Rhonda D ^a,b  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c OHIO UNIVERSITY   (United States)

^d OHIO UNIVERSITY   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

^f University of Alabama at Birmingham   (United States)

^g BIRMINGHAM VA MEDICAL CENTER   (United States)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE 1; ADIPOSE TG LIPASE; BETA 3 ADRENERGIC RECEPTOR; DIACYLGLYCEROL ACYLTRANSFERASE 2; ESTROGEN; FATTY ACID; FATTY ACID SYNTHASE; FRUCTOSE 2,6 BISPHOSPHATE; GLUCOKINASE; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER 2; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HORMONE SENSITIVE LIPASE; INSULIN; LIPID; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOTRANSFERASE; PROTEIN; PYRUVATE KINASE LIVER AND RED BLOOD CELL; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; FRUCTOSE 2,6-DIPHOSPHATE; FRUCTOSE BISPHOSPHATE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ESTROGEN THERAPY; EXPERIMENTAL FATTY LIVER; FEMALE; GENE SILENCING; GLYCOLYSIS; HORMONE RESISTANCE; HORMONE SUBSTITUTION; INSULIN SENSITIVITY; LIPID LIVER LEVEL; LIPID STORAGE; LIPID TRANSPORT; LIPOGENESIS; LIPOLYSIS; LIVER METABOLISM; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL; GENETICS; LIVER; METABOLISM; NONALCOHOLIC FATTY LIVER; OVARIECTOMY; PHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FRUCTOSEDIPHOSPHATES; GENE KNOCKDOWN TECHNIQUES; GLUCOKINASE; GLYCOLYSIS; GROWTH HORMONE; INSULIN; LIPOGENESIS; LIVER; MALE; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; OVARIECTOMY; RECEPTORS, SOMATOTROPIN; RNA, MESSENGER;

EID: 84961401194     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0370     Document Type: Article

References (61)

1. Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis 2015;239:192-202
2. Lade A, Noon LA, Friedman SL. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol 2014;26:100-107
3. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013;10:656-665
4. Fuchs CD, Claudel T, Trauner M. Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD. Trends Endocrinol Metab 2014;25: 576-585
5. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-1351
6. Rui L. Energy metabolism in the liver. Compr Physiol 2014;4:177-197
7. Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 2003;29:478-485
8. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014;146:726-735
9. Wilke MS, French MA, Goh YK, Ryan EA, Jones PJ, Clandinin MT. Synthesis of specific fatty acids contributes to VLDL-triacylglycerol composition in humans with and without type 2 diabetes. Diabetologia 2009;52:1628-1637
10. LeRoith D. Clinical relevance of systemic and local IGF-I: lessons from animal models. Pediatr Endocrinol Rev 2008;5(Suppl. 2):739-743
11. Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S, LeRoith D. Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res 2010;20:1-7
12. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 1991;73:1081-1088
13. Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord 1999;23:260-271
14. De Marinis L, Bianchi A, Mancini A, et al. Growth hormone secretion and leptin in morbid obesity before and after biliopancreatic diversion: relationships with insulin and body composition. J Clin Endocrinol Metab 2004;89:174-180
15. Hazlehurst JM, Tomlinson JW. Non-alcoholic fatty liver disease in common endocrine disorders. Eur J Endocrinol 2013;169:R27-R37
16. Nishizawa H, Iguchi G, Murawaki A, et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur J Endocrinol 2012;167:67-74
17. Gardner CJ, Irwin AJ, Daousi C, et al. Hepatic steatosis, GH deficiency and the effects of GH replacement: a Liverpool magnetic resonance spectroscopy study. Eur J Endocrinol 2012;166:993-1002
18. Diniz RD, Souza RM, Salvatori R, et al. Liver status in congenital, untreated, isolated GH deficiency. Endocr Connect 2014;3:132-137
19. Laron Z, Ginsberg S, Webb M. Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion-preliminary report. Growth Horm IGF Res 2008;18:434-438
20. Xu L, Xu C, Yu C, et al. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study. PLoS One 2012;7:e44136
21. García-Galiano D, Sánchez-Garrido MA, Espejo I, et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 2007;17:493-503
22. Ichikawa T, Nakao K, Hamasaki K, et al. Role of growth hormone, insulinlike growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int 2007;1:287-294
23. Runchey SS, Boyko EJ, Ioannou GN, Utzschneider KM. Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States. J Gastroenterol Hepatol 2014;29:589-596
24. Sumida Y, Yonei Y, Tanaka S, et al. Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease. Hepatol Res. 28 August 2014 [Epub ahead of print]. DOI: 10.1111/hepr.12408
25. Völzke H, Nauck M, Rettig R, et al. Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. Eur J Endocrinol 2009;161:705-713
26. Owen C, Lees EK, Mody N, Delibegovic M. Regulation of growth hormone induced JAK2 and mTOR signalling by hepatic protein tyrosine phosphatase 1B. Diabetes Metab 2015;41:95-101
27. Rotwein P. Mapping the growth hormone-Stat5b-IGF-I transcriptional circuit. Trends Endocrinol Metab 2012;23:186-193
28. Bielohuby M, Sawitzky M, Stoehr BJ, et al. Lack of dietary carbohydrates induces hepatic growth hormone (GH) resistance in rats. Endocrinology 2011; 152:1948-1960
29. Dong XC, Copps KD, Guo S, et al. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab 2008;8:65-76
30. Madsen M, Krusenstjerna-Hafstrøm T, Møller L, et al. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial. J Clin Endocrinol Metab 2012;97:1227-1235
31. Yang T, Householder LA, Lubbers ER, et al. Growth hormone receptor antagonist transgenic mice are protected from hyperinsulinemia and glucose intolerance despite obesity when placed on a HF diet. Endocrinology 2015;156: 555-564
32. Qin Y, Tian YP. Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats. Lipids Health Dis 2010;9:78
33. List EO, Palmer AJ, Berryman DE, Bower B, Kelder B, Kopchick JJ. Growth hormone improves body composition, fasting blood glucose, glucose tolerance and liver triacylglycerol in a mouse model of diet-induced obesity and type 2 diabetes. Diabetologia 2009;52:1647-1655
34. List EO, Berryman DE, Funk K, et al. The role of GH in adipose tissue: lessons from adipose-specific GH receptor gene-disrupted mice. Mol Endocrinol 2013;27:524-535
35. Cordoba-Chacon J, Gahete MD, McGuinness OP, Kineman RD. Differential impact of selective GH deficiency and endogenous GH excess on insulin-mediated actions in muscle and liver of male mice. Am J Physiol Endocrinol Metab 2014;307: E928-E934
36. Van Schaftingen E, Lederer B, Bartrons R, Hers HG. A kinetic study of pyrophosphate: fructose-6-phosphate phosphotransferase from potato tubers. Application to a microassay of fructose 2, 6-bisphosphate. Eur J Biochem 1982; 129:191-195
37. Bederman IR, Foy S, Chandramouli V, Alexander JC, Previs SF. Triglyceride synthesis in epididymal adipose tissue: contribution of glucose and non-glucose carbon sources. J Biol Chem 2009;284:6101-6108
38. Hsieh CW, Millward CA, DeSantis D, et al. Reduced milk triglycerides in mice lacking phosphoenolpyruvate carboxykinase in mammary gland adipocytes and white adipose tissue contribute to the development of insulin resistance in pups. J Nutr 2009;139:2257-2265
39. Brunengraber DZ, McCabe BJ, Kasumov T, Alexander JC, Chandramouli V, Previs SF. Influence of diet on the modeling of adipose tissue triglycerides during growth. Am J Physiol Endocrinol Metab 2003;285:E917-E925
40. Venken K, Schuit F, Van Lommel L, et al. Growth without growth hormone receptor: estradiol is a major growth hormone-independent regulator of hepatic IGF-I synthesis. J Bone Miner Res 2005;20:2138-2149
41. Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Méndez-Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010;9:402-409
42. Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21:138-143
43. Barros RP, Gustafsson JA. Estrogen receptors and the metabolic network. Cell Metab 2011;14:289-299
44. Fan Y, Menon RK, Cohen P, et al. Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem 2009;284:19937-19944
45. Sos BC, Harris C, Nordstrom SM, et al. Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. J Clin Invest 2011;121:1412-1423
46. Zhu L, Brown WC, Cai Q, et al. Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance. Diabetes 2013;62:424-434
47. Varlamov O, Bethea CL, Roberts CT Jr. Sex-specific differences in lipid and glucose metabolism. Front Endocrinol (Lausanne) 2014;5:241
48. Chong MF, Hodson L, Bickerton AS, et al. Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 d of high-carbohydrate feeding. Am J Clin Nutr 2008;87:817-823
49. Kim YD, Li T, Ahn SW, et al. Orphan nuclear receptor small heterodimer partner negatively regulates growth hormone-mediated induction of hepatic gluconeogenesis through inhibition of signal transducer and activator of transcription 5 (STAT5) transactivation. J Biol Chem 2012;287:37098-37108
50. Okar DA, Manzano A, Navarro-Sabatè A, Riera L, Bartrons R, Lange AJ. PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2, 6-bisphosphate. Trends Biochem Sci 2001;26:30-35
51. Barclay JL, Nelson CN, Ishikawa M, et al. GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology 2011;152: 181-192
52. Cui Y, Hosui A, Sun R, et al. Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepato-logy 2007;46:504-513
53. Mueller KM, Kornfeld JW, Friedbichler K, et al. Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocel-lular carcinoma in mice. Hepatology 2011;54:1398-1409
54. Yakar S, Setser J, Zhao H, et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 2004;113:96-105
55. Xu X, Hueckstaedt LK, Ren J. Deficiency of insulin-like growth factor 1 attenuates aging-induced changes in hepatic function: role of autophagy. J Hepatol 2013;59:308-317
56. List EO, Berryman DE, Funk K, et al. Liver-specific GH receptor gene-disrupted (LiGHRKO) mice have decreased endocrine IGF-I, increased local IGF-I, and altered body size, body composition, and adipokine profiles. Endocrinology 2014;155:1793-1805
57. Louet JF, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: insight from human and genetic mouse models. Curr Atheroscler Rep 2004;6:180-185
58. Xu J, Messina JL. Crosstalk between growth hormone and insulin signaling. Vitam Horm 2009;80:125-153
59. Morral N, Edenberg HJ, Witting SR, Altomonte J, Chu T, Brown M. Effects of glucose metabolism on the regulation of genes of fatty acid synthesis and tri-glyceride secretion in the liver. J Lipid Res 2007;48:1499-1510
60. De Ceuninck F, Kargar C, Ilic C, et al. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol 2013;168:339-353
61. Peter A, Stefan N, Cegan A, et al. Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 2011;96:E1126-E1130